Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saredutant Maintenance in MDD
NCT00336713Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Saredutant 100 mg with Placebo (2 arms). Primary endpoint: Time to relapse of depressive symptoms at 52 weeks. Started May 2006; status: completed.
02
Drugs
saredutant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00336713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336713.